---
schema_version: "secwatch.filing_event.v1"
accession: "0001818382-24-000146"
form_type: "8-K"
ticker: "HUMA"
cik: "0001818382"
company_name: "Humacyte, Inc."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:28:21.986425+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Humacyte ATEV meets Phase 3 endpoints in hemodialysis access; superiority over standard of care

## Summary
- ATEV showed superior functional patency at 6 months (81.3% vs 66.4%) and secondary patency at 12 months (68.3% vs 62.2%); p=0.0071.
- ATEV also demonstrated significantly longer hemodialysis duration over 12 months (p=0.0162).
- Company plans to discuss potential market authorization pathway with FDA soon.
- More adverse events were reported in the ATEV arm compared to the fistula arm.
- Over 800,000 Americans have end-stage renal disease; ATEV is an off-the-shelf bioengineered vessel.

## SEC filing metadata
- accession: 0001818382-24-000146
- form_type: 8-K
- ticker: HUMA
- cik: 0001818382
- company_name: Humacyte, Inc.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/0001818382-24-000146-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818382/000181838224000146/huma-20240731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818382-24-000146
- JSON: https://secwatch.observer/filing/0001818382-24-000146.json
- Plain text: https://secwatch.observer/filing/0001818382-24-000146.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.